Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05275075 · ClinicalTrials.gov registry record
Identify microRNAs in Cachexia in Pancreatic Carcinoma
A clinical trial of Resectable Pancreatic Adenocarcinoma, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT05275075: Recruiting study of Resectable Pancreatic Adenocarcinoma, sponsored by University of Oklahoma.
NCT05275075 is a study of Resectable Pancreatic Adenocarcinoma that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 100 participants, below the 118-participant average among 5 other Resectable Pancreatic Adenocarcinoma trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05275075, a study of Resectable Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.
Primary Outcome
Evaluate weight loss and the markers of cachexia, albumin and psoas cross-sectional area, to see if African Americans with pancreatic cancer patients experience Grade I-IV cachexia at a higher frequency than other racial groups.
Conditions Studied
Interventions
- OTHER Pancreatic cancer microRNA and messenger RNA expression.
Study Locations (1)
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-12-07 |
| Est. Completion | 2029-05-01 |
What NCT05275075 shows while recruiting
NCT05275075 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 118-participant average among 5 other Resectable Pancreatic Adenocarcinoma trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Resectable Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Pancreatic cancer microRNA and messenger RNA expression. is the first listed.
NCT05275075 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT05275075 about?
NCT05275075 is a clinical study titled "Identify microRNAs in Cachexia in Pancreatic Carcinoma". The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.
What is the current status of trial NCT05275075?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2022-12-07. Estimated completion is 2029-05-01.
What conditions does trial NCT05275075 study?
This clinical trial studies the following conditions: Resectable Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT05275075?
The interventions under investigation include: Pancreatic cancer microRNA and messenger RNA expression. (OTHER).
Who is sponsoring clinical trial NCT05275075?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05275075 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Resectable Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
RECRUITING · Phase 2
-
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI